Cellectis: encouraging data in breast cancer

(CercleFinance.com) - Cellectis managed to escape the gloom on the Paris stock market on Wednesday after presenting preclinical evidence of the efficacy of its CAR T cells against breast cancer.


The biotech company, which specializes in genome editing, said today it had published a scientific paper in Science Advances suggesting that CAR T 'MUC1' cells edited by its 'Talen' technology platform.

According to the French 'biotech', these genetically modified T lymphocytes could represent a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC), whose treatment options are limited.

The idea is to arm CAR T cells with multiple synergistic functionalities to overcome the immunosuppressive tumor microenvironment of solid tumors.

'The complexity of solid tumors diminishes the efficacy of CAR T cell therapies', explains Piril Erler, Cellectis researcher.

"This preclinical study demonstrates that Talen-mediated multiplex editing can help CAR T cells create an effective anti-tumor response to eliminate breast tumors", she adds.

Cellectis even believes it can further reduce the treatment dose by injecting CAR T cells intratumorally, while continuing to treat distant tumors.

Worldwide, breast cancer remains the most common malignancy in women.

Of all subtypes, triple-negative breast cancer is the most aggressive, with high metastatic potential and very low survival rates.

Despite some targeted therapies under investigation, surgery, chemotherapy and radiotherapy remain the norm, with limited success.

In this respect, CAR T cell therapies could be a promising alternative, emphasizes Cellectis.

Following these announcements, the biotech company's shares were up 0.5% on Wednesday morning on the Paris Bourse, after having gained up to 2.7% during the morning, while the CAC Mid & Small index was down 0.3%.

Copyright (c) 2024 CercleFinance.com. All rights reserved.